Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Whether working on dynamic discoveries in the lab, connecting with students and faculty or pursuing his passion for nature photography, acclaimed biomedical researcher John Kuriyan is inspired by his recent move to join Vanderbilt as the new dean of the School of Medicine Basic Sciences and Distinguished University Professor.

https://news.vanderbilt.edu/2023/04/03/new-dean-of-basic-sciences-aims-to-take-vanderbilt-to-the-next-level-in-biomedical-research-drug-discovery/

Mon, 04/03/2023 - 12:00

Cancer_Cell_Biology_Research_Program

Amy Wolf

Locked

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma

The primary objective of this phase IIb/III study is to evaluate whether the combination of
lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma
(LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when
compared to doxorubicin administered as a single agent.

Disease Sites: Not Available

Phase: II/III

Investigator: Davis, Elizabeth

NCTID: NCT06088290

Protocol No: VICC-DTSAR23232

Learn More

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109,
which is a recombinant humanized tetravalent antibody targeting the human death receptor 5
(DR5).

Disease Sites: Not Available

Phase: I

Investigator: Davis, Elizabeth

NCTID: NCT03715933

Protocol No: VICCMDP2287

Learn More

A Randomized Phase III of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Disease Sites: Not Available

Phase: III

Investigator: Davis, Elizabeth

NCTID: NCT06422806

Protocol No: VICC-NTSAR24139

Learn More

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

A Randomized Phase III of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

A Randomized Phase III of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Clinical Trial Flowcharts for Referring Physicians

Clinical Trial Flowcharts for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)